BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 19617318)

  • 1. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable Alzheimer disease.
    Nelissen N; Van Laere K; Thurfjell L; Owenius R; Vandenbulcke M; Koole M; Bormans G; Brooks DJ; Vandenberghe R
    J Nucl Med; 2009 Aug; 50(8):1251-9. PubMed ID: 19617318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An exploratory efficacy study of the amyloid imaging agent [(18)F]flutemetamol in Japanese Subjects.
    Senda M; Yamamoto Y; Sasaki M; Yamane T; Brooks DJ; Farrar G; McParland B; Heurling K
    Ann Nucl Med; 2015 Jun; 29(5):391-9. PubMed ID: 25874747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of qualitative and quantitative imaging characteristics of [11C]PiB and [18F]flutemetamol in normal control and Alzheimer's subjects.
    Mountz JM; Laymon CM; Cohen AD; Zhang Z; Price JC; Boudhar S; McDade E; Aizenstein HJ; Klunk WE; Mathis CA
    Neuroimage Clin; 2015; 9():592-8. PubMed ID: 26640770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of [¹⁸F]flutemetamol in wild-type rodents and its binding to beta amyloid deposits in a mouse model of Alzheimer's disease.
    Snellman A; Rokka J; Lopez-Picon FR; Eskola O; Wilson I; Farrar G; Scheinin M; Solin O; Rinne JO; Haaparanta-Solin M
    Eur J Nucl Med Mol Imaging; 2012 Nov; 39(11):1784-95. PubMed ID: 22801729
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-mortem analyses of PiB and flutemetamol in diffuse and cored amyloid-β plaques in Alzheimer's disease.
    Ikonomovic MD; Buckley CJ; Abrahamson EE; Kofler JK; Mathis CA; Klunk WE; Farrar G
    Acta Neuropathol; 2020 Oct; 140(4):463-476. PubMed ID: 32772265
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [18F]Flutemetamol amyloid-beta PET imaging compared with [11C]PIB across the spectrum of Alzheimer's disease.
    Hatashita S; Yamasaki H; Suzuki Y; Tanaka K; Wakebe D; Hayakawa H
    Eur J Nucl Med Mol Imaging; 2014 Feb; 41(2):290-300. PubMed ID: 24085503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: a phase 2 trial.
    Vandenberghe R; Van Laere K; Ivanoiu A; Salmon E; Bastin C; Triau E; Hasselbalch S; Law I; Andersen A; Korner A; Minthon L; Garraux G; Nelissen N; Bormans G; Buckley C; Owenius R; Thurfjell L; Farrar G; Brooks DJ
    Ann Neurol; 2010 Sep; 68(3):319-29. PubMed ID: 20687209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data.
    Lundqvist R; Lilja J; Thomas BA; Lötjönen J; Villemagne VL; Rowe CC; Thurfjell L
    J Nucl Med; 2013 Aug; 54(8):1472-8. PubMed ID: 23740104
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of
    Zeydan B; Schwarz CG; Przybelski SA; Lesnick TG; Kremers WK; Senjem ML; Kantarci OH; Min PH; Kemp BJ; Jack CR; Kantarci K; Lowe VJ
    J Nucl Med; 2022 Aug; 63(8):1239-1244. PubMed ID: 34916245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amyloid imaging in cognitively normal older adults: comparison between (18)F-flutemetamol and (11)C-Pittsburgh compound B.
    Adamczuk K; Schaeverbeke J; Nelissen N; Neyens V; Vandenbulcke M; Goffin K; Lilja J; Hilven K; Dupont P; Van Laere K; Vandenberghe R
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):142-151. PubMed ID: 26260650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consideration of optimal time window for Pittsburgh compound B PET summed uptake measurements.
    McNamee RL; Yee SH; Price JC; Klunk WE; Rosario B; Weissfeld L; Ziolko S; Berginc M; Lopresti B; Dekosky S; Mathis CA
    J Nucl Med; 2009 Mar; 50(3):348-55. PubMed ID: 19223409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Can target-to-pons ratio be used as a reliable method for the analysis of [11C]PIB brain scans?
    Edison P; Hinz R; Ramlackhansingh A; Thomas J; Gelosa G; Archer HA; Turkheimer FE; Brooks DJ
    Neuroimage; 2012 Apr; 60(3):1716-23. PubMed ID: 22306804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flutemetamol (18F): a β-amyloid positron emission tomography tracer for Alzheimer's and dementia diagnosis.
    de Lartigue J
    Drugs Today (Barc); 2014 Mar; 50(3):219-29. PubMed ID: 24696867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging β-amyloid using [(18)F]flutemetamol positron emission tomography: from dosimetry to clinical diagnosis.
    Heurling K; Leuzy A; Zimmer ER; Lubberink M; Nordberg A
    Eur J Nucl Med Mol Imaging; 2016 Feb; 43(2):362-373. PubMed ID: 26440450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spatial Normalization of
    Lilja J; Leuzy A; Chiotis K; Savitcheva I; Sörensen J; Nordberg A
    J Nucl Med; 2019 Feb; 60(2):285-291. PubMed ID: 29903930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head-to-head comparison of 11C-PiB and 18F-AZD4694 (NAV4694) for β-amyloid imaging in aging and dementia.
    Rowe CC; Pejoska S; Mulligan RS; Jones G; Chan JG; Svensson S; Cselényi Z; Masters CL; Villemagne VL
    J Nucl Med; 2013 Jun; 54(6):880-6. PubMed ID: 23575995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18).
    Wong DF; Rosenberg PB; Zhou Y; Kumar A; Raymont V; Ravert HT; Dannals RF; Nandi A; Brasić JR; Ye W; Hilton J; Lyketsos C; Kung HF; Joshi AD; Skovronsky DM; Pontecorvo MJ
    J Nucl Med; 2010 Jun; 51(6):913-20. PubMed ID: 20501908
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Using a reference tissue model with spatial constraint to quantify [11C]Pittsburgh compound B PET for early diagnosis of Alzheimer's disease.
    Zhou Y; Resnick SM; Ye W; Fan H; Holt DP; Klunk WE; Mathis CA; Dannals R; Wong DF
    Neuroimage; 2007 Jun; 36(2):298-312. PubMed ID: 17449282
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Automated quantification of 18F-flutemetamol PET activity for categorizing scans as negative or positive for brain amyloid: concordance with visual image reads.
    Thurfjell L; Lilja J; Lundqvist R; Buckley C; Smith A; Vandenberghe R; Sherwin P
    J Nucl Med; 2014 Oct; 55(10):1623-8. PubMed ID: 25146124
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Head-to-head comparison of 11C-PiB and 18F-FC119S for Aβ imaging in healthy subjects, mild cognitive impairment patients, and Alzheimer's disease patients.
    Byun BH; Kim BI; Park SY; Ko IO; Lee KC; Kim KM; Kim YK; Lee JY; Bu SH; Kim JH; Chi DY; Ha JH; Lim SM
    Medicine (Baltimore); 2017 Mar; 96(12):e6441. PubMed ID: 28328855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.